PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
34328253-15	2021	Unbound dolutegravir >= 431 nM induced expression of CYP3A4 (>= two-fold) in a dose-dependent manner, while 1.44 muM of unbound dolutegravir induced CYP2B6 expression 2.2 +- 0.3-fold (P = 0.0004).	dolutegravir	8-20	cytochrome P450 family 2 subfamily B member 6	Homo sapiens	149-155	
34328253-15	2021	Unbound dolutegravir >= 431 nM induced expression of CYP3A4 (>= two-fold) in a dose-dependent manner, while 1.44 muM of unbound dolutegravir induced CYP2B6 expression 2.2 +- 0.3-fold (P = 0.0004).	dolutegravir	128-140	cytochrome P450 family 2 subfamily B member 6	Homo sapiens	149-155	
32667979-2	2021	In a Phase 1 dolutegravir-efavirenz interaction study, mean dolutegravir Cmin decreased by 60% and 85% among CYP2B6 normal and slow/intermediate metabolizers, respectively.	dolutegravir	13-25	cytochrome P450 family 2 subfamily B member 6	Homo sapiens	109-115	
32960272-0	2021	CYP2B6 Genotype and Weight Gain Differences Between Dolutegravir and Efavirenz.	dolutegravir	52-64	cytochrome P450 family 2 subfamily B member 6	Homo sapiens	0-6	
35099526-0	2022	Corrigendum to: CYP2B6 Genotype and Weight Gain Differences Between Dolutegravir and Efavirenz.	dolutegravir	68-80	cytochrome P450 family 2 subfamily B member 6	Homo sapiens	16-22